Meloxicam
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) that inhibits COX-2; it exhibits anti-inflammatory, analgesic, antipyretic, neuroprotective, antioxidative, and hepatoprotective activities. In animal models of Parkinson’s disease, meloxicam inhibits MPTP-induced motor dysfunction and increases levels of tyrosine hydroxylase. In animal models of CCL(4)-induced liver damage, meloxicam increases levels of superoxide dismutase, catalase, and glutathione-S-transferase and decreases levels of malondialdehyde, prostaglandin E2 (PGE2), and activated caspase 3.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18943506
| Cas No. |
71125-38-7 |
|---|---|
| Purity |
≥98% |
| Formula |
C14H13N3O4S2 |
| Formula Wt. |
351.41 |
| Chemical Name |
4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1, 1-dioxide |
| IUPAC Name |
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1λ6,2-benzothiazine-3-carboxamide |
| Synonym |
Metacam; Mobec |
| Melting Point |
254°C (dec) |
| Solubility |
Insol in water. Sol in DMF and DMSO. |
| Appearance |
Slight Yellow Powder |
Tasaki Y, Yamamoto J, Omura T, et al. Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinsons disease model. Neurosci Lett. 2012 Jul 11;521(1):15-9. PMID: 22617635.
Edfawy M, Hassan MH, Mansour A, et al. Meloxicam modulates oxidative stress status, inhibits prostaglandin E2, and abrogates apoptosis in carbon tetrachloride-induced rat hepatic injury. Int J Toxicol. 2012 Jun;31(3):276-86. PMID: 22556387.
Noble S, Balfour JA. Meloxicam. Drugs. 1996 Mar;51(3):424-32. PMID: 8882380.
Malreddy PR, Coetzee JF, Kukanich B, Gehring R. Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. J Vet Pharmacol Ther. 2013 Feb;36(1):14-20. PMID: 22372845.
